StockNews.AI
PHGE
StockNews.AI
153 days

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

1. BiomX will report Q4 and full year 2024 results on March 25, 2025. 2. Initial results from Phase 2 trial on diabetic foot osteomyelitis are anticipated. 3. Company focuses on engineered phage therapies targeting pathogenic bacteria. 4. BiomX's technology aims to treat chronic diseases with significant unmet needs. 5. Details available on their website and through a future conference call.

Earnings
+5.65%Current Return
VS
+0.07%S&P 500
$0.596303/19 12:42 PM EDTEvent Start
$0.6303/20 07:10 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming trial results can significantly influence investor perception. Positive outcomes might lead to increased stock demand, similar to historical cases where clinical trial results boosted similar biotech stocks.

How important is it?

The scheduled financial results and trial data release are pivotal for investors. This regular update can drive market trends and valuations for PHGE.

Why Short Term?

The March 25 announcement is imminent, influencing immediate market sentiment. A successful Phase 2 trial could lead to swift investor confidence and stock price movement.

Related Companies

NASDAQ: INONASDAQ: CRISNASDAQ: AGTC
NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025. A press release reporting the results will be available in the Investors section of the Company’s website at www.biomx.com. The Company intends to host a conference call and a live audio webcast on a later date to report fourth quarter and full year 2024 financial results, in conjunction with its expected announcement of initial topline results from its Phase 2 trial for subjects with diabetic foot osteomyelitis. About BiomXBiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release. BiomX, Inc.Ben Cohenbenc@biomx.com CORE IRMike Masonir-biomx@biomx.com

Related News